Source: International Congress 2019 – Novel targets and mechanisms in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Mcnamara (South San Francisco, United States of America), C. Campbell (South San Francisco, United States of America), A. Heinichen (South San Francisco, United States of America), E. Situ (South San Francisco, United States of America), W. Lee (South San Francisco, United States of America), E. Kaufman (South San Francisco, United States of America), P. Fatheree (South San Francisco, United States of America), M. Kleinschek (South San Francisco, United States of America). The potent and lung-selective inhaled pan JAK inhibitor TD-8236 limits airway inflammation without affecting systemic immunity in mice. 4952

Member's Comments

No comment yet.

Related content which might interest you: TD-0903, an inhaled JAK inhibitor in development for COVID-19, blocks ARDS-relevant hyperinflammation and lung injury in primary human immune and airway epithelial cells Source: Virtual Congress 2021 – Emerging respiratory diseases: state-of-the-art studies of SARS-CoV-2 infection Year: 2021 Anti IL-17 with or without Rho kinase inhibitor in mice with chronic allergic pulmonary inflammation Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017 Arsenic trioxide, a potent inhibitor of NF-κB, abrogates allergen-induced airway hyperresponsiveness and inflammation Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment Year: 2007 The pan janus kinase (JAK) inhibitor KN-002 suppresses inflammatory mediator release from severe asthma bronchial epithelial cells. Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021 HIF-1α inhibitor, 2ME2, attenuates airway inflammation and hyperresponsiveness in allergic airway disease Source: Annual Congress 2008 - Novel therapeutic approaches and immunological mechanisms in airway cell pathobiology Year: 2008 The therapeutic efficacy of OAT-889 (dual AMCase/CHIT1 inhibitor) in comparison to montelukast in HDM-induced model of chronic airway inflammation in mice Source: International Congress 2017 – Asthma: mechanisms and treatment Year: 2017 AZD7624, an inhaled p38 inhibitor for COPD, attenuates lung and systemic inflammation after LPS Challenge in humans Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 Effects of CHF6297, a potent and selective p38a MAPK inhibitor, in murine models of steroid resistant lung inflammation Source: International Congress 2017 – Towards new anti-inflammatory and anti-fibrotic agents Year: 2017 The inhaled PDE4 inhibitor GSK256066 significantly inhibits airway responses following allergen challenge in asthmatics Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008 A dual role of IL-6 signalling and STAT-3 activation on airway inflammation versus airway hyperresponsiveness in a murine model of asthma Source: Eur Respir J 2002; 20: Suppl. 38, 568s Year: 2002 Effect of a pan-JAK inhibitor pyridone 6 on airway responses in murine asthma model Source: Annual Congress 2010 - Asthma: basic science and clinical studies Year: 2010 Inhibition of the alternative complement pathway abolishes the development of airway hyperresponsiveness (AHR) and inflammation Source: Eur Respir J 2004; 24: Suppl. 48, 348s Year: 2004 Dose-dependent effects of muIL-13Rα2, a potent IL-13 neutraliser, on the phenotype of an acute allergic airways inflammation model in BALB/c mice Source: Annual Congress 2004 - Animal models of asthma and chronic bronchitis and their relevance in pulmonary pharmacology Year: 2004 The p38 MAP kinase inhibitor dilmapimod ameliorates airway inflammation induced by ozone challenge in healthy volunteers Source: Annual Congress 2012 - Treatment of asthma, bronchiectasis and cough: inhaler use Year: 2012 The effect of GSK2190915, a 5-lipoxygenase activating protein inhibitor, on the early asthmatic response to inhaled allergen Source: Annual Congress 2011 - Asthma management and response Year: 2011 In vivo blockade of CTLA-4 counteracts inhalation tolerance and leads to development of allergic airway inflammation in mice repeatedly exposed to aerosolized ovalbumin Source: Eur Respir J 2004; 24: Suppl. 48, 6s Year: 2004 The inhaled PDE4 inhibitor UK-500,001 does not significantly inhibit airway responses to allergen and histamine Source: Annual Congress 2007 - New drugs for asthma Year: 2007 The protective effects of SIGIRR on flagellin-induced acute inflammation of the airway in mice Source: Annual Congress 2008 - Mechanisms of respiratory infections: interaction between the pathogen and the host Year: 2008 Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels Source: Eur Respir J 2002; 19: 952-958 Year: 2002 Inhibition of c-kit tyrosine kinase by sunitinib alleviates airway remodeling in a mouse model of chronic asthma Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009